The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective
In patients with diabetes mellitus, cardiovascular (CV) disease is the leading cause of morbidity and mortality. A multitude of contemporary antidiabetic agents presents different CV safety profiles. Metformin forms the cornerstone agent to reduce CV events. Newer agents, such as glucagon‐like pepti...
Gespeichert in:
| Veröffentlicht in: | Clinical cardiology (Mahwah, N.J.) N.J.), 2017-11, Vol.40 (11), p.970-973 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 973 |
|---|---|
| container_issue | 11 |
| container_start_page | 970 |
| container_title | Clinical cardiology (Mahwah, N.J.) |
| container_volume | 40 |
| creator | Fatima, Saeeda Jameel, Ayesha Ayesha, FNU Menzies, Dhananjai J. |
| description | In patients with diabetes mellitus, cardiovascular (CV) disease is the leading cause of morbidity and mortality. A multitude of contemporary antidiabetic agents presents different CV safety profiles. Metformin forms the cornerstone agent to reduce CV events. Newer agents, such as glucagon‐like peptide‐1 agonists and sodium‐glucose cotransporter‐2 inhibitors, have appealing CV benefits. Insulin, dipeptidyl peptidase‐4 inhibitors, and sulfonylureas have neutral CV effects. Cardiologists should familiarize themselves with these agents to promote comprehensive CV care in patients with diabetes mellitus. |
| doi_str_mv | 10.1002/clc.22781 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6490350</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1932844555</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4431-931c626e1a9fb595a22a75cdf0571bf317ab78f4d9a0448cd08d336153975a8f3</originalsourceid><addsrcrecordid>eNp1kbtuFDEUhi1ERJZAwQsgSxRAMYmvY7uJFK24RFqJJtSWx2PvOpoZD7YnaDsegifkSXDYEIVIVKc4nz795_wAvMLoFCNEzuxgTwkREj8BK6woaaSg4ilYIdyiRhGpjsHznK8riiShz8AxkZJhQuQKmKudg3kXfAnTFs4mmT5sRxgmWOqiJGfK6KYCo4dlPztIYB9M54rLcHTDEMqSf_34eQGtSX2IQ9yGXN5mOLuUZ2dLuHEvwJE3Q3Yv7-YJ-Prxw9X6c7P58ulyfbFpLGMUN4pi25LWYaN8xxU3hBjBbe8RF7jzFAvTCelZrwxiTNoeyZ7SFnOqBDfS0xNwfvDOSze63tbUyQx6TmE0aa-jCfrfzRR2ehtvdMsUohxVwbs7QYrfFpeLHkO29UgzubhkfftZyRjnvKJvHqHXcUlTPa9SgiqJCW4r9f5A2RRzTs7fh8FI3xana3H6T3GVff0w_T35t6kKnB2A72Fw-_-b9HqzPih_A3Mbo50</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1973981216</pqid></control><display><type>article</type><title>The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Fatima, Saeeda ; Jameel, Ayesha ; Ayesha, FNU ; Menzies, Dhananjai J.</creator><creatorcontrib>Fatima, Saeeda ; Jameel, Ayesha ; Ayesha, FNU ; Menzies, Dhananjai J.</creatorcontrib><description>In patients with diabetes mellitus, cardiovascular (CV) disease is the leading cause of morbidity and mortality. A multitude of contemporary antidiabetic agents presents different CV safety profiles. Metformin forms the cornerstone agent to reduce CV events. Newer agents, such as glucagon‐like peptide‐1 agonists and sodium‐glucose cotransporter‐2 inhibitors, have appealing CV benefits. Insulin, dipeptidyl peptidase‐4 inhibitors, and sulfonylureas have neutral CV effects. Cardiologists should familiarize themselves with these agents to promote comprehensive CV care in patients with diabetes mellitus.</description><identifier>ISSN: 0160-9289</identifier><identifier>ISSN: 1932-8737</identifier><identifier>EISSN: 1932-8737</identifier><identifier>DOI: 10.1002/clc.22781</identifier><identifier>PMID: 28841228</identifier><language>eng</language><publisher>New York: Wiley Periodicals, Inc</publisher><subject>Antidiabetics ; Attitude of Health Personnel ; Biomarkers - blood ; Blood Glucose - drug effects ; Blood Glucose - metabolism ; Cardiologists - psychology ; Cardiovascular Diseases - diagnosis ; Cardiovascular Diseases - mortality ; Cardiovascular Diseases - prevention & control ; Cardiovascular Risk ; Cardiovascular Safety ; Clinical Competence ; Diabetes ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - diagnosis ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - mortality ; GLP-1 receptor agonists ; Glycated Hemoglobin - metabolism ; Health Knowledge, Attitudes, Practice ; Humans ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Novel Antiglycemic Drugs ; Review ; Reviews ; Risk Factors ; Treatment Outcome ; Type 2 Diabetes Mellitus</subject><ispartof>Clinical cardiology (Mahwah, N.J.), 2017-11, Vol.40 (11), p.970-973</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4431-931c626e1a9fb595a22a75cdf0571bf317ab78f4d9a0448cd08d336153975a8f3</citedby><cites>FETCH-LOGICAL-c4431-931c626e1a9fb595a22a75cdf0571bf317ab78f4d9a0448cd08d336153975a8f3</cites><orcidid>0000-0002-8677-6410</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490350/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490350/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,27924,27925,45574,45575,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28841228$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fatima, Saeeda</creatorcontrib><creatorcontrib>Jameel, Ayesha</creatorcontrib><creatorcontrib>Ayesha, FNU</creatorcontrib><creatorcontrib>Menzies, Dhananjai J.</creatorcontrib><title>The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective</title><title>Clinical cardiology (Mahwah, N.J.)</title><addtitle>Clin Cardiol</addtitle><description>In patients with diabetes mellitus, cardiovascular (CV) disease is the leading cause of morbidity and mortality. A multitude of contemporary antidiabetic agents presents different CV safety profiles. Metformin forms the cornerstone agent to reduce CV events. Newer agents, such as glucagon‐like peptide‐1 agonists and sodium‐glucose cotransporter‐2 inhibitors, have appealing CV benefits. Insulin, dipeptidyl peptidase‐4 inhibitors, and sulfonylureas have neutral CV effects. Cardiologists should familiarize themselves with these agents to promote comprehensive CV care in patients with diabetes mellitus.</description><subject>Antidiabetics</subject><subject>Attitude of Health Personnel</subject><subject>Biomarkers - blood</subject><subject>Blood Glucose - drug effects</subject><subject>Blood Glucose - metabolism</subject><subject>Cardiologists - psychology</subject><subject>Cardiovascular Diseases - diagnosis</subject><subject>Cardiovascular Diseases - mortality</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Cardiovascular Risk</subject><subject>Cardiovascular Safety</subject><subject>Clinical Competence</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - diagnosis</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - mortality</subject><subject>GLP-1 receptor agonists</subject><subject>Glycated Hemoglobin - metabolism</subject><subject>Health Knowledge, Attitudes, Practice</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Novel Antiglycemic Drugs</subject><subject>Review</subject><subject>Reviews</subject><subject>Risk Factors</subject><subject>Treatment Outcome</subject><subject>Type 2 Diabetes Mellitus</subject><issn>0160-9289</issn><issn>1932-8737</issn><issn>1932-8737</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kbtuFDEUhi1ERJZAwQsgSxRAMYmvY7uJFK24RFqJJtSWx2PvOpoZD7YnaDsegifkSXDYEIVIVKc4nz795_wAvMLoFCNEzuxgTwkREj8BK6woaaSg4ilYIdyiRhGpjsHznK8riiShz8AxkZJhQuQKmKudg3kXfAnTFs4mmT5sRxgmWOqiJGfK6KYCo4dlPztIYB9M54rLcHTDEMqSf_34eQGtSX2IQ9yGXN5mOLuUZ2dLuHEvwJE3Q3Yv7-YJ-Prxw9X6c7P58ulyfbFpLGMUN4pi25LWYaN8xxU3hBjBbe8RF7jzFAvTCelZrwxiTNoeyZ7SFnOqBDfS0xNwfvDOSze63tbUyQx6TmE0aa-jCfrfzRR2ehtvdMsUohxVwbs7QYrfFpeLHkO29UgzubhkfftZyRjnvKJvHqHXcUlTPa9SgiqJCW4r9f5A2RRzTs7fh8FI3xana3H6T3GVff0w_T35t6kKnB2A72Fw-_-b9HqzPih_A3Mbo50</recordid><startdate>201711</startdate><enddate>201711</enddate><creator>Fatima, Saeeda</creator><creator>Jameel, Ayesha</creator><creator>Ayesha, FNU</creator><creator>Menzies, Dhananjai J.</creator><general>Wiley Periodicals, Inc</general><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8677-6410</orcidid></search><sort><creationdate>201711</creationdate><title>The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective</title><author>Fatima, Saeeda ; Jameel, Ayesha ; Ayesha, FNU ; Menzies, Dhananjai J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4431-931c626e1a9fb595a22a75cdf0571bf317ab78f4d9a0448cd08d336153975a8f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antidiabetics</topic><topic>Attitude of Health Personnel</topic><topic>Biomarkers - blood</topic><topic>Blood Glucose - drug effects</topic><topic>Blood Glucose - metabolism</topic><topic>Cardiologists - psychology</topic><topic>Cardiovascular Diseases - diagnosis</topic><topic>Cardiovascular Diseases - mortality</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Cardiovascular Risk</topic><topic>Cardiovascular Safety</topic><topic>Clinical Competence</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - diagnosis</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - mortality</topic><topic>GLP-1 receptor agonists</topic><topic>Glycated Hemoglobin - metabolism</topic><topic>Health Knowledge, Attitudes, Practice</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Novel Antiglycemic Drugs</topic><topic>Review</topic><topic>Reviews</topic><topic>Risk Factors</topic><topic>Treatment Outcome</topic><topic>Type 2 Diabetes Mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fatima, Saeeda</creatorcontrib><creatorcontrib>Jameel, Ayesha</creatorcontrib><creatorcontrib>Ayesha, FNU</creatorcontrib><creatorcontrib>Menzies, Dhananjai J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cardiology (Mahwah, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fatima, Saeeda</au><au>Jameel, Ayesha</au><au>Ayesha, FNU</au><au>Menzies, Dhananjai J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective</atitle><jtitle>Clinical cardiology (Mahwah, N.J.)</jtitle><addtitle>Clin Cardiol</addtitle><date>2017-11</date><risdate>2017</risdate><volume>40</volume><issue>11</issue><spage>970</spage><epage>973</epage><pages>970-973</pages><issn>0160-9289</issn><issn>1932-8737</issn><eissn>1932-8737</eissn><abstract>In patients with diabetes mellitus, cardiovascular (CV) disease is the leading cause of morbidity and mortality. A multitude of contemporary antidiabetic agents presents different CV safety profiles. Metformin forms the cornerstone agent to reduce CV events. Newer agents, such as glucagon‐like peptide‐1 agonists and sodium‐glucose cotransporter‐2 inhibitors, have appealing CV benefits. Insulin, dipeptidyl peptidase‐4 inhibitors, and sulfonylureas have neutral CV effects. Cardiologists should familiarize themselves with these agents to promote comprehensive CV care in patients with diabetes mellitus.</abstract><cop>New York</cop><pub>Wiley Periodicals, Inc</pub><pmid>28841228</pmid><doi>10.1002/clc.22781</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-8677-6410</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0160-9289 |
| ispartof | Clinical cardiology (Mahwah, N.J.), 2017-11, Vol.40 (11), p.970-973 |
| issn | 0160-9289 1932-8737 1932-8737 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6490350 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals; PubMed Central |
| subjects | Antidiabetics Attitude of Health Personnel Biomarkers - blood Blood Glucose - drug effects Blood Glucose - metabolism Cardiologists - psychology Cardiovascular Diseases - diagnosis Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cardiovascular Risk Cardiovascular Safety Clinical Competence Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - mortality GLP-1 receptor agonists Glycated Hemoglobin - metabolism Health Knowledge, Attitudes, Practice Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Novel Antiglycemic Drugs Review Reviews Risk Factors Treatment Outcome Type 2 Diabetes Mellitus |
| title | The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A32%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20shifting%20paradigm%20in%20the%20treatment%20of%20type%202%20diabetes%20mellitus%E2%80%94A%20cardiologist's%20perspective&rft.jtitle=Clinical%20cardiology%20(Mahwah,%20N.J.)&rft.au=Fatima,%20Saeeda&rft.date=2017-11&rft.volume=40&rft.issue=11&rft.spage=970&rft.epage=973&rft.pages=970-973&rft.issn=0160-9289&rft.eissn=1932-8737&rft_id=info:doi/10.1002/clc.22781&rft_dat=%3Cproquest_pubme%3E1932844555%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1973981216&rft_id=info:pmid/28841228&rfr_iscdi=true |